Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
Merck
Colorcon
AstraZeneca

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Parke Davis Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Parke Davis
International Patents:49
US Patents:1
Tradenames:77
Ingredients:68
NDAs:104

Drugs and US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis PROCAN procainamide hydrochloride CAPSULE;ORAL 087502-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis SECOBARBITAL SODIUM secobarbital sodium CAPSULE;ORAL 084762-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis PROLOID thyroglobulin TABLET;ORAL 002245-010 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis UTICORT betamethasone benzoate LOTION;TOPICAL 017528-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis MEPROBAMATE meprobamate TABLET;ORAL 084744-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Parke Davis ERYC 125 erythromycin CAPSULE, DELAYED REL PELLETS;ORAL 062648-001 Oct 24, 1985 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis CHOLYBAR cholestyramine BAR, CHEWABLE;ORAL 071621-001 May 26, 1988 4,778,676   Start Trial
Parke Davis FEMPATCH estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020417-001 Dec 3, 1996 5,006,342   Start Trial
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 4,260,769   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 5,084,479*PED   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 4,894,476*PED   Start Trial
Parke Davis NEURONTIN gabapentin SOLUTION;ORAL 021129-001 Mar 2, 2000 6,054,482*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PARKE DAVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19

Supplementary Protection Certificates for Parke Davis Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0770388 PA2009004,C0770388 Lithuania   Start Trial PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
0473687 SPC/GB98/030 United Kingdom   Start Trial PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0809498 10C0038 France   Start Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
0502314 C300095 Netherlands   Start Trial PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0136011 99C0003 Belgium   Start Trial PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
McKesson
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.